EMA Releases API Bioequivalence Studies Guidance
Article
PTSM: Pharmaceutical Technology Sourcing and Management
PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-08-05-2015
Volume 11
Issue 8
The agency has released guidance on bioequivalence studies for asenapine, prasugrel, sitagliptin, and zonisamide.
The European Medicines Agency (EMA) opened up for consultation product-specific guidance documents on bioequivalence studies for the active substances asenapine, prasugrel, sitagliptin, and zonisamide. The release of the guidance documents follows finalization of bioequivalence guidance on 16 active substances in 2014 and 2015.
The guidance documents, which can be found on EMA’s website, are available for comment until Nov. 1, 2015.
Source: EMA
Articles in this issue
CDMOs Move Slowly with Expansion Plans
Accelerating Continuous API Synthesis
BioOutsource Opens New Facility in Glasgow
Needle in the Haystack, or Rembrandt in the Attic? Drug Repurposing's New Strategy
Silicone Rubber Pieces Spur Recall of Teva Product
Baxter Recalls IV Solution for Container and Particulate Issues
Indian API Manufacturer Cited for Recordkeeping Failures
Xcelience Makes Investment in Powdersize
FDA Issues Quality Metrics Draft Guidance Document for Comment
EMA Issues Guideline on Fast Tracking Drugs for Unmet Needs
SafeBridge Updates Potent API and Drug Manufacturer Status
Capsugel Expands Capabilities at its Edinburgh Facility
DPx Holdings Sells Fine Chemicals Business
World Courier Receives UK Wholesale Distribution Authorisation
CSafe Adds Service Center for Controlled-Temperature Shipping in Switzerland
Recent Videos
